Early detection of breast cancer using total biochemical analysis of peripheral blood components: A preliminary study

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Zelig, Udi ^a   Barlev, Eyal ^b,c   Bar, Omri ^a   Gross, Itai ^d   Flomen, Felix ^a   Mordechai, Shaul ^e   Kapelushnik, Joseph ^c   Nathan, Ilana ^e   Kashtan, Hanoch ^b,c   Wasserberg, Nir ^b,c   Madhala Givon, Osnat ^b,c  

^a Todos Medical Ltd   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Breast cancer detection; Infrared spectroscopy; Mononuclear cells; Plasma

Indexed keywords

SELENIDE; ZINC; TUMOR MARKER;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BIOCHEMICAL ANALYSIS; BLOOD ANALYSIS; BLOOD COMPONENT; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; FEMALE; HUMAN; INFRARED SPECTROSCOPY; LYMPH NODE; MALE; MALIGNANT NEOPLASTIC DISEASE; MONTE CARLO METHOD; PERIPHERAL BLOOD MONONUCLEAR CELL; SENSITIVITY AND SPECIFICITY; BIOPSY; BLOOD; BREAST NEOPLASMS; CASE CONTROL STUDY; EARLY CANCER DIAGNOSIS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BIOPSY; BLOOD CHEMICAL ANALYSIS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; RISK FACTORS; ROC CURVE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; YOUNG ADULT;

EID: 84929407724     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1414-7     Document Type: Article

References (44)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
2. Smith RA, Cokkinides V, Brooks D, Saslow D, Shah M, Brawley OW. Cancer screening in the United States, 2011: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2011;61(1):8-30.
3. Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005;353(17):1773-83.
4. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011;1, CD001877.
5. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348.
6. Hooley RJ, Andrejeva L, Scoutt LM. Breast cancer screening and problem solving using mammography, ultrasound, and magnetic resonance imaging. Ultrasound Q. 2011;27(1):23-47.
7. Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23(33):8469-76.
8. Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer. 2007;43(13):1905-17.
9. Lee CH, Dershaw DD, Kopans D, Evans P, Monsees B, Monticciolo D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010;7(1):18-27.
10. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem. 2006;52(3):345-51.
11. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical O: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-312.
12. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5(11):845-56.
13. Farlow EC, Patel K, Basu S, Lee BS, Kim AW, Coon JS, et al. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res. 2010;16(13):3452-62.
14. Lumachi F, Marino F, Orlando R, Chiara GB, Basso SM. Simultaneous multianalyte immunoassay measurement of five serum tumor markers in the detection of colorectal cancer. Anticancer Res. 2012;32(3):985-8.
15. Diem M, Griffiths PR, Chalmers JM. Vibrational spectroscopy for medical diagnosis. 40th ed. Chichester: Wiley; 2008.
16. Bunaciu AA, Hoang VD, Aboul-Enein HY. Applications of FTIR Spectrophotometry in Cancer Diagnostics. Crit Rev Anal Chem. 2014;45(2):156-65.
17. Simonova D, Karamancheva I. Application of Fourier Transform Infrared Spectroscopy for Tumor Diagnosis. Biotechnol Biotechnol Equip. 2013;27(6):4200-7.
18. Zelig U, Mordechai S, Shubinsky G, Sahu RK, Huleihel M, Leibovitz E, et al. Pre-screening and follow-up of childhood acute leukemia using biochemical infrared analysis of peripheral blood mononuclear cells. Biochim Biophys Acta. 2011;1810(9):827-35.
19. Ostrovsky E, Zelig U, Gusakova I, Ariad S, Mordechai S, Nisky I, et al. Detection of cancer using advanced computerized analysis of infrared spectra of peripheral blood. IEEE Trans Biomed Eng. 2013;60(2):343-53.
20. Lasch P. Spectral pre-processing for biomedical vibrational spectroscopy and microspectroscopic imaging. Chemometr Intell Lab Syst. 2012;117:100-14.
21. Bird B, Miljkovic M, Romeo MJ, Smith J, Stone N, George MW, et al. Infrared micro-spectral imaging: distinction of tissue types in axillary lymph node histology. BMC Clin Pathol. 2008;8(1):8.
22. Toyran N, Lasch P, Naumann D, Turan B, Severcan F. Early alterations in myocardia and vessels of the diabetic rat heart: an FTIR microspectroscopic study. Biochem J. 2006;397(3):427-36.
23. Duda RO, Hart PE, Stork DG. Pattern classification. 2nd ed. New York: Wiley; 2001.
24. Liu KZ, Xu M, Scott DA. Biomolecular characterisation of leucocytes by infrared spectroscopy. Br J Haematol. 2007;136(5):713-22.
25. Movasaghi Z, Rehman S, Rehman IU. Fourier Transform Infrared (FTIR) Spectroscopy of Biological Tissues. Appl Spectros Rev. 2008;43:134-79.
26. Townsend CM, Beauchamp RD, Evers BM, Mattox KL. Sabiston textbook of surgery. In: W.B. Saunders Company. 19th ed. 2004. p. 838-40.
27. Mantsch HH, Chapman D. Infrared spectroscopy of biomolecules. New York: John Wiley; 1996.
28. Bogomolny E, Argov S, Mordechai S, Huleihel M. Monitoring of viral cancer progression using FTIR microscopy: a comparative study of intact cells and tissues. Biochim Biophys Acta. 2008;1780(9):1038-46.
29. Sahu R, Mordechai S. Fourier transform infrared spectroscopy in cancer detection. Future Oncol. 2005;1(5):635-47.
30. Andrus PG. Cancer monitoring by FTIR spectroscopy. Technol Cancer Res Treat. 2006;5(2):157-67.
31. Whitehead RH, Thatcher J, Teasdale C, Roberts GP, Hughes LE. T and B lymphocytes in breast cancer stage relationship and abrogation of T-lymphocyte depression by enzyme treatment in vitro. Lancet. 1976;1(7955):330-3.
32. Shimokawara I, Imamura M, Yamanaka N, Ishii Y, Kikuchi K. Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: an immunoperoxidase study with anti-human T- and B-cell sera. Cancer. 1982;49(7):1456-64.
33. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108(3):804-11.
34. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9(2):606-12.
35. Leong PP, Mohammad R, Ibrahim N, Ithnin H, Abdullah M, Davis WC, et al. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol Lett. 2006;102(2):229-36.
36. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169(5):2756-61.
37. Tokuno K, Hazama S, Yoshino S, Yoshida S, Oka M. Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer. Anticancer Res. 2009;29(5):1527-32.
38. Ju S, Qiu H, Zhou X, Zhu B, Lv X, Huang X, et al. CD13 + CD4 + CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients. Cell Cycle. 2009;8(16):2578-85.
39. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res. 2003;90:127-56.
40. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y. CD4 + CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol. 2006;176(3):1582-7.
41. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27(45):5932-43.
42. Jesneck JL, Mukherjee S, Yurkovetsky Z, Clyde M, Marks JR, Lokshin AE, et al. Do serum biomarkers really measure breast cancer? BMC Cancer. 2009;9:164.
43. Yu J, Sun J, Wang SE, Li H, Cao S, Cong Y, et al. Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis. Clin Dev Immunol. 2011;2011:469135.
44. Grieb G, Merk M, Bernhagen J, Bucala R. Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect. 2010;23(4):257-64.